Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats
- PMID: 36047723
- PMCID: PMC9841803
- DOI: 10.33549/physiolres.934869
Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats
Abstract
Non-alcoholic fatty liver disease (NAFLD) is linked to type 2 diabetes mellitus (T2DM), obesity, and insulin resistance. The Rho/ROCK pathway had been involved in the pathophysiology of diabetic complications. This study was designed to assess the possible protective impacts of the Rho/Rho-associated coiled-coil containing protein kinase (Rho/ROCK) inhibitor fasudil against NAFLD in T2DM rats trying to elucidate the underlying mechanisms. Animals were assigned into control rats, non-treated diabetic rats with NAFLD, and diabetic rats with NAFLD that received fasudil treatment (10 mg/kg per day) for 6 weeks. The anthropometric measures and biochemical analyses were performed to assess metabolic and liver function changes. The inflammatory and oxidative stress markers and the histopathology of rat liver tissues were also investigated. Groups with T2DM showed increased body weight, serum glucose, and insulin resistance. They exhibited disturbed lipid profile, enhancement of inflammatory cytokines, and deterioration of liver function. Fasudil administration reduced body weight, insulin resistance, and raised liver enzymes. It improved the disturbed lipid profile and attenuated liver inflammation. Moreover, it slowed down the progression of high fat diet (HFD)-induced liver injury and reduced the caspase-3 expression. The present study demonstrated beneficial amelioration effect of fasudil on NAFLD in T2DM. The mechanisms underlying these impacts are improving dyslipidemia, attenuating oxidative stress, downregulated inflammation, improving mitochondrial architecture, and inhibiting apoptosis.
Conflict of interest statement
There is no conflict of interest.
Figures







Similar articles
-
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.Curr Med Sci. 2022 Jun;42(3):513-519. doi: 10.1007/s11596-022-2573-9. Epub 2022 Apr 22. Curr Med Sci. 2022. PMID: 35451807
-
Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.Drug Dev Res. 2022 May;83(3):735-744. doi: 10.1002/ddr.21905. Epub 2021 Dec 19. Drug Dev Res. 2022. PMID: 34927282 Free PMC article.
-
Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Oct 28;20(40):14950-7. doi: 10.3748/wjg.v20.i40.14950. World J Gastroenterol. 2014. PMID: 25356056 Free PMC article.
-
Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases.Diabetes Metab J. 2021 Sep;45(5):655-674. doi: 10.4093/dmj.2021.0197. Epub 2021 Sep 30. Diabetes Metab J. 2021. PMID: 34610720 Free PMC article. Review.
-
Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells.Metab Syndr Relat Disord. 2023 Mar;21(2):71-78. doi: 10.1089/met.2022.0069. Epub 2023 Jan 10. Metab Syndr Relat Disord. 2023. PMID: 36625898 Review.
Cited by
-
Fasudil Ameliorates Methotrexate-Induced Hepatotoxicity by Modulation of Redox-Sensitive Signals.Pharmaceuticals (Basel). 2022 Nov 19;15(11):1436. doi: 10.3390/ph15111436. Pharmaceuticals (Basel). 2022. PMID: 36422565 Free PMC article.
-
Curcumin Analog J7 Attenuates Liver Fibrosis and Metabolic Dysregulation in a Rat Model of Type 2 Diabetes via Modulation of TGF-β/Smad and NF-κB/BCL-2/BAX Pathways.Drug Des Devel Ther. 2025 Apr 1;19:2411-2432. doi: 10.2147/DDDT.S511372. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40190815 Free PMC article.
-
Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation-a systematic review.Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2681-2699. doi: 10.1007/s00210-023-02834-6. Epub 2023 Nov 15. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37966572
-
Vagal Stimulation Ameliorates Non-Alcoholic Fatty Liver Disease in Rats.Biomedicines. 2023 Dec 8;11(12):3255. doi: 10.3390/biomedicines11123255. Biomedicines. 2023. PMID: 38137476 Free PMC article.
-
Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease.Physiol Res. 2024 Apr 30;73(2):265-271. doi: 10.33549/physiolres.935164. Physiol Res. 2024. PMID: 38710056 Free PMC article.
References
-
- Akshintala D, Chugh R, Amer F, Cusi K. Nonalcoholic fatty liver disease: the overlooked complication of type 2 diabetes. Endotext [Internet] 2019
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials